Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
Apr 26 BMY Bristol, Sanofi, Takeda gain positive CHMP recommendations
Apr 26 BMY The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Apr 26 BMY CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Apr 26 BMY Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Apr 26 BMY Q1 2024 Bristol-Myers Squibb Co Earnings Call
Apr 26 BMY Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat
Apr 25 BMY Bristol Myers Squibb stock tumbles on cost-cutting initiative
Apr 25 BMY Bristol-Myers Squibb Stock: Gloomy Q1 Earnings Trigger Justified Sell-Off
Apr 25 BMY Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Apr 25 BMY Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Apr 25 BMY Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Apr 25 BMY Bristol-Myer Squibb Company (BMY) Q1 2024 Earnings Call Transcript
Apr 25 BMY Update: Bristol-Myers Squibb Swings to Q1 Non-GAAP Loss, Revenue Rises; Provides 2024 Guidance -- Shares Fall
Apr 25 BMY Bristol Myers (BMY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Apr 25 BMY Why Bristol Myers Squibb Stock Is Sinking Today
Apr 25 BMY Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Apr 25 BMY Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
Apr 25 BMY Bristol Myers Squibb (BMY) Q1 2024 Earnings Call Transcript
Apr 25 BMY Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts
Apr 25 BMY Is Bristol Myers Squibb Stock a Millionaire Maker?
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags